Autopsy report · NCT02111096
A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus
Cause of deathFutility
“The overall benefit-risk profile did not support continued development of LY2409021 for type 2 diabetes.”
Life of this trial
- Ran for about 1 year 5 months before it stopped.
- 174 participants enrolled.
- Results were posted on the registry 2 years 7 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2409021; Sitagliptin; Placebo; Metformin; Sulfonylurea
- Participants
- 174
- Sites
- 33
- Countries
- Greece, Puerto Rico, Taiwan, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.